Renalytix Share Discussion Threads

[mr roper] 22/4/2021 08:21

I recollect one of the calls with Randy Barron on it who when talking about the opportunity here went along the lines of Renx being a company that could go from $0 revenue to $300-500m overnight and no one can see it coming.

Today’s news is like someone setting a flare off, if investors can’t see the flare...well...

[lottsgold] 22/4/2021 08:13

Totally agree this will be led by the US

[wan] 22/4/2021 08:03

No doubt that it will be very well received when the US market opens.

[mr roper] 22/4/2021 08:01

It sure is. Absolutely stunning

[someuwin] 22/4/2021 08:00

Amazing news.

[mr roper] 22/4/2021 07:42

Currently going through final approval with fda

[longshanks] 22/4/2021 07:40

I thought KidneyIntelX had already got FDA approval

[mr roper] 22/4/2021 07:40

You’d think so, Russ. This kind of additional validation as well as the news earlier this month can only build the case for the fda to approve in the near future.

If they can get 53000 tests a year out of a patient population of 20m from this contract, that’s 50m.

106000 -100m usd approx
212000 (approx 1% of the possible market) -200m
318000 -300m

[ramridge] 22/4/2021 07:37

Currently forecast revenue for 2021 is $4.7m
Even a tiny fraction of the numbers quoted by Mr Roper makes revenues go up by at least 10x
Bonkers as he said.

[faz] 22/4/2021 07:36

It seems the US Govt has not waited for the FDA to make the deicsion for them. We would all expect FDA approval to be granted, given the close working RENX has put in over the last three years but this news should really show the market 'revenue time' is about to start , get on board!

[homebrewruss] 22/4/2021 07:33

Great news! Does this also bode well for FDA approval?

[wan] 22/4/2021 07:28

Excellent news today, big in itself, as exemplified by the formation of a market access team focused on contracting with VA, DoD, and IHS facilities.

It's only part of the initial stage of commercialisation, but wow, what a start!

Not to mention the recognition and kudos in securing such an important contract.

Very well done to the Renalytix team!

[mr roper] 22/4/2021 07:27

Last time I looked, there was approx 1.3m active military personnel in the US army, approx 700-800,000 reservists.
Veterans is a whole different ball game, edit - Last census has this as approx 18m personnel.

If they get 1% of that total tested via KidneyIntelX then it’s bonkers.

So, it’s a huge, huge opportunity.

[ramridge] 22/4/2021 07:20

Wow! excellent news. But what does it mean from a revenue perspective?
'$950 per reportable result' it says. How many reportable results can we expect in a year?
Haven't got a clue! Anyone willing to make an intelligent guess?

[longshanks] 22/4/2021 07:18

Great news and shows what a strong product they have.Revenue growth in the coming year should be impressive.

[mr roper] 22/4/2021 07:08

“Executing on our market access strategy represents a substantial commercial opportunity for RenalytixAI."

[mr roper] 22/4/2021 07:06

Have to admit I never saw this coming. Absolutely massive news.

[lottsgold] 22/4/2021 07:04

Looks to be big news! Is government contract!

[wan] 21/4/2021 07:53

News coverage of one of the recent AstraZeneca studies I highlighted in post 1004 -

New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
Mitchel L. Zoler, PhD

April 20, 2021

Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) was safe and effective for slowing progression of chronic kidney disease (CKD) and the development of end-stage renal disease for patients with immunoglobulin A (IgA) nephropathy, a new analysis of the DAPA-CKD trial indicates.

"Dapagliflozin may be a novel therapeutic option to slow kidney function decline in patients with IgA nephropathy," Hiddo J. L. Heerspink, PhD, said at the International Society of Nephrology (ISN): 2021 World Congress.

This prespecified analysis suggests that other agents in the SGLT2 inhibitor class may also be effective in treating this disease, the researchers said.

"The patients in DAPA-CD were clearly not as optimized [with regard to their treatments] as they are in any of the current IgA nephropathy treatment trials," said Barratt, professor of renal medicine at the University of Leicester, Leicester, United Kingdom, who was not involved with the study.

"We hope that [dapagliflozin and other SGLT2 inhibitors] will add value, because we are desperate for treatments for patients with IgA nephropathy. The study I want to see would add dapagliflozin on top of standard care and see whether it truly adds value," he concluded.

Full story -

In my view, this is where KidneyIntelX could be deployed to optimise treatment (and might well be given the collaboration with AstraZeneca)

[jsredbird] 21/4/2021 03:49

I don’t see how that’s possible. Rental lyrics currently has a market cap around 800-900 million. That is without FDA approval and any widespread commercial distribution. One could speculate that the multiple is at least 10 X their current market cap. How does a $2.3 billion company even approach that number?

[w13ken] 20/4/2021 13:56

Motley Fool have been speculating on who Fulgent might buy now that they have expressrd an interest in a takeover. RENX fits the bill. Fulgent market cap $2.6bn.

"Of the publicly traded companies that are small enough to be potential targets, three spring to mind for what they would offer in terms of technology, geography, or both. Bionano Genomics (NASDAQ:BNGO) is a leader in optical genome mapping. Renalytix (NASDAQ:RNLX) uses artificial intelligence for patients with chronic kidney disease, and is based in Europe. Finally, Burning Rock Biotech (NASDAQ:BNR) is a Chinese company that specializes in genetic testing to identify therapies for late-stage cancer patients."

[mr roper] 20/4/2021 10:34

Keeping it wide until the Yanks get out of bed.

[tradertrev] 20/4/2021 09:32

Spread is ludicrous for a £700m mkt cap company. Company needs to change the quote from being market-maker driven to order-book driven. This would increase short term price volatility but substantially reduce the dealing spread and improve liquidity. Problem is, the financial adviser is one of those market-makers extracting a king's ransom from the spread, so is unlikely to advise such a move.

[wan] 20/4/2021 08:53

I also noted recently that AstraZeneca have been busy in the area of kidney disease, with quite a long list of study results published in issue: April, 2021 -